Sudo Biosciences is thrilled to announce a significant funding milestone, successfully raising $116 million in its latest financing round. As a pioneering biopharmaceutical company, Sudo Biosciences is dedicated to transforming patient outcomes through the innovative design and development of best-in-class medicines. Our research primarily focuses on targeting the pseudokinase domain of tyrosine kinase 2 (TYK2), a critical player in cytokine signaling pathways that are intricately associated with a variety of immune-mediated inflammatory conditions. With this new capital infusion, we aim to accelerate the advancement of our lead programs, driving them through clinical trials to ultimately deliver groundbreaking treatments for patients suffering from these debilitating diseases. This funding not only strengthens our resolve to innovate but also highlights the confidence that our investors place in our mission. As we move forward, Sudo Biosciences remains committed to pushing the boundaries of science and medicine, harnessing our expertise and cutting-edge research to deliver therapies that can meaningfully change lives. The investment will enable us to expand our research capabilities, attract top-tier talent, and enhance our operational infrastructure, positioning us favorably for the next stages of our growth. We are excited about the journey ahead and look forward to sharing our progress as we endeavor to make a lasting impact in the biopharmaceutical landscape.

Sudo Biosciences Secures $116M in Series B Funding to Advance Breakthrough Medicines Targeting TYK2
Get the full Sudo Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Windmill
Windmill is the first context graph for your people: a continuous, cited understanding of your workforce so HR can lead strategically, managers can see their teams clearly, and every person's work speaks for itself.
$12.0M Seed
today

Hypervision Surgical
Hypervision Surgical Ltd is a spin-out company formed from King's College London and was founded by a team of clinicians, medical imaging and artificial intelligence (AI) experts. Based on safe light alone, our goal is to equip clinicians with advanced computer-assisted tissue analysis for improved surgical precision and patient safety.
$23.0M Series a
today

Eccasion
We accelerate the electric vehicle movement, by providing access to reliable and affordable used electric vehicles. We do this by creating a personal search assignment with you and provide the best possible matches of all the available vehicles sold through closed markets by lease companies. We provide the vehicles including all benefits, but without the detour of going through a car dealer. No hidden fees or mandatory service packages, but standard (battery) warranty, 14 day trial period, transport and cleaning included. Our customers experience a radical transparent process where we tell everything we know about the car, from damages, maintenance, common failures and even all our costs involved. The result; Our customers receive a reliable and affordable car, bought online without any risks and delivered to their doorstep. 100% 5/5 ratings (https://nl.trustpilot.com/review/eccasion.com) We focus only on electric vehicles, because this is the future of the car market, it is the most reliable and low maintenance car on the market, it is our focus and above all.. It is the most sustainable ride right now!
$3.8M Seed
today

Predictheon
Predictheon started in 2015 when a group of medical doctors, anesthesiologists to be specific, together with math modelers, and computer engineers decided to move forward their prior research track. The original goal was to create a new concept in patient care management, one that seeks to integrate predictive analytics with real-time monitoring, in order to give clinicians meaningful information about a patient’s future behavior. Such information would allow an anesthesia provider to anticipate a clinically significant change, or possibly an upcoming negative event before it occurs. This concept arose from the desire to better understand how the current state of the patient will change in the next 5 or 10 minutes from now, allowing the anesthesia provider to proactively act ahead of time, to prevent a potentially severe adverse side effect before it happens. The concept expanded to other areas of healthcare where we are actively searching for predictive solutions (perioperative blood management, altered postoperative cognition, critical care, oncology, …). Predictheon was created as a company in 2019. We verified our idea by continuously collecting "outcome-oriented" high-resolution data from a vast number of patients, analyzing those data under a population perspective, using classical modeling or AI-derived methods, and have now come up with a powerful “predictive engine” based on mathematical models describing the relations between patients and outcomes. When we apply our unique solution to a new patient, our models can predict future behavior, including potentially severe side effects before they happen. Predictheon's individualized patient care now results in optimal decision making and increased patient safety during a medical procedure that requires the patient to have sedation or general anesthesia and will expand into other areas of patient care.
$2.1M Seed
today

RedpineAI
Only 1% of the world's data is openly available on the Internet. We unlock the rest, to power your AI development. Redpine powers AI builders and autonomous agents with access to licensed, high-quality and multimodal data - securely and at scale. The platform empowers content owners across domains - including copyright holders and proprietary data providers - to offer controlled and compliant access to their data, unlocking value for both data owners and AI builders. Founded in 2024 and headquartered in Stockholm, Redpine’s team brings deep expertise from leading organizations in data science, machine learning, and AI product development. The company is backed by prominent investors from OpenAI, Spotify, Perplexity, Xiaomi, Sana, and more.
$8.0M Seed
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Nervonik, Inc. United States | Series b | $52.5M | 1d ago |
| 2 | ![]() A1A株式会社 Japan | Series b | $650.0M | 2d ago |
| 3 | ![]() stockeeper 스탁키퍼 South Korea | Series b | $4.6M | 2d ago |
| 4 | ![]() INCAPTO Spain | Series b | $11.8M | 4d ago |
| 5 | ![]() Orkes United States | Series b | $60.0M | 4d ago |




